A 58-year-old male with COPD on long-term oxygen therapy presents with a 10-day history of productive cough with greenish sputum, fever (38.5°C), and dyspnea. Chest X-ray shows bilateral lower lobe infiltrates. Sputum culture yields a gram-negative rod that is oxidase-positive, grows on MacConkey agar as a non-lactose fermenter, and produces a characteristic fruity/grape-like odor. The organism is resistant to ceftazidime and ciprofloxacin. Which is the most appropriate initial empiric antibiotic regimen for this patient?

Explanation

## Identification of Organism **Key Point:** The clinical presentation and microbiological findings are pathognomonic for *Pseudomonas aeruginosa*: - Gram-negative rod - Oxidase-positive (critical differentiator) - Non-lactose fermenter on MacConkey - Fruity/grape-like odor (pyoverdine pigment) - Resistance to beta-lactams and fluoroquinolones ## Antibiotic Selection in Multidrug-Resistant P. aeruginosa **High-Yield:** When P. aeruginosa demonstrates resistance to cephalosporins (ceftazidime) and fluoroquinolones (ciprofloxacin), it suggests multidrug-resistant (MDR) phenotype. The organism likely retains susceptibility to carbapenems and aminoglycosides. **Clinical Pearl:** Meropenem (a carbapenem) penetrates lung tissue well and is the beta-lactam of choice for resistant P. aeruginosa respiratory infections. Combination therapy with an aminoglycoside (amikacin or tobramycin) provides synergy and reduces resistance emergence. ## Rationale for Correct Answer | Regimen | Mechanism | Why Used Here | |---------|-----------|---------------| | Meropenem + amikacin/tobramycin | Carbapenem (cell wall) + aminoglycoside (protein synthesis) | Synergistic; covers MDR P. aeruginosa; aminoglycoside achieves high lung concentrations | | Piperacillin-tazobactam | Beta-lactam/beta-lactamase inhibitor | Organism already resistant to ceftazidime; likely cross-resistant | | Ceftriaxone + gentamicin | Third-generation cephalosporin | Ceftriaxone has poor P. aeruginosa coverage; organism is cephalosporin-resistant | | Cefixime + levofloxacin | Oral cephalosporin + fluoroquinolone | Organism is fluoroquinolone-resistant; inadequate for severe pneumonia | **Key Point:** Aminoglycosides (tobramycin preferred in respiratory infections due to superior lung bioavailability) should be given at high doses (15 mg/kg/day) and monitored for renal/ototoxicity. ## Risk Factors in This Patient - Chronic lung disease (COPD) with oxygen dependence - Prolonged antibiotic exposure (likely prior courses) - Hospitalization risk (ICU-level infection) These factors increase the likelihood of MDR P. aeruginosa colonization.